Literature DB >> 17641492

Vitiligo.

Hagit Matz1, Ethel Tur.   

Abstract

Vitiligo is an acquired depigmentary disorder of the skin that results from the selective destruction of melanocytes. The etiology of vitiligo is poorly understood. There appears to be a genetic predisposition, but additional factors are probably involved. The purpose of this article is to outline the factors that might play a role in the development of vitiligo. These include trauma such as vaccination, radiotherapy, and sun exposure, malignancies and treatment of malignancies like lymphoma or melanoma, bone marrow transplantation, interferon, interleukin, and other drugs, psychological factors, endocrine disease and cytotoxic compounds that cause contact vitiligo. We hope future research will shed more light on the subject and identify the precipitating factors, since in the majority of vitiligo cases the contributing factors are as yet unidentified.

Entities:  

Mesh:

Year:  2007        PMID: 17641492     DOI: 10.1159/000106412

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  4 in total

1.  Chronic diseases among vitiligo patients. A case control study.

Authors:  Abdullah O Al Houssien; Rana O Al Houssien; Waleed Al Ajroush; Hassan S Al Kahtani
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484

2.  The Study of Serum Level of Interleukin-2, Interleukin-6, and Tumor Necrosis Factor-alpha in Stable and Progressive Vitiligo Patients from Sina Hospital in Tabriz, Iran.

Authors:  Mohammad Reza Ranjkesh; Mahya Rahimi Partovi; Mehrdad Pashazadeh
Journal:  Indian J Dermatol       Date:  2021 Jul-Aug       Impact factor: 1.494

3.  Childhood vitiligo: treatment paradigms.

Authors:  Amrinder Jit Kanwar; M Sendhil Kumaran
Journal:  Indian J Dermatol       Date:  2012-11       Impact factor: 1.494

4.  Kaliziri extract upregulates tyrosinase, TRP-1, TRP-2 and MITF expression in murine B16 melanoma cells.

Authors:  Adila Tuerxuntayi; Yong-qiang Liu; Ablajan Tulake; Maidina Kabas; Aiden Eblimit; Haji Akber Aisa
Journal:  BMC Complement Altern Med       Date:  2014-05-22       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.